NCT03866382 2026-04-16
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
16 trialsNCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02496208 2026-04-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03793166 2026-04-13
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07510334 2026-04-03
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Not yet recruiting
NCT07128680 2026-02-27
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07383441 2026-02-03
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03274258 2025-12-03
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04388852 2025-11-21
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06866262 2025-09-09
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT05361720 2025-07-23
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03829111 2024-07-03
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
Phase 1 Completed
NCT06399419 2024-05-30
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel, Inc.
Phase 1 Recruiting